Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants

Next Previous
Trial Profile

A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DC-853 (Primary) ; Digoxin (Primary) ; Midazolam (Primary) ; Repaglinide (Primary) ; Rosuvastatin (Primary)
  • Indications Immunological disorders; Psoriasis
  • Focus Pharmacokinetics
  • Sponsors DICE Therapeutics

Most Recent Events

  • 24 Jan 2025 Status changed from recruiting to completed.
  • 03 Oct 2024 Planned number of patients changed from 32 to 48.
  • 03 Oct 2024 Planned End Date changed from 1 Oct 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top